5 completed, 3 recruiting, 2 unknown, 1 active not recruiting. 11 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 5, Recruiting 3, Unknown 2, Active not recruiting 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Glomerulosclerosis, Focal Segmental: new trials by email Literature Review of Glomerulosclerosis, Focal Segmental trials Research Report on Glomerulosclerosis, Focal Segmental
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) BI 764198, Placebo - Focal Segmental Glomerulosclerosis | Phase 3 | Recruiting | Boehringer Ingelheim | 286 | 2026-02-16 | 2026-10-28 |
| A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis BAT4406F, Placebos - Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 / Phase 3 | Recruiting | Bio-Thera Solutions | 192 | 2025-10-26 | 2026-04-03 |
| REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE) Prednisone - Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change | Phase 3 | Active not recruiting | The Hospital for Sick Children | 50 | 2024-11-01 | 2026-05-11 |
| A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB DMX-200, Placebo - FSGS | Phase 3 | Recruiting | Dimerix Bioscience Pty Ltd | 286 | 2022-05-30 | 2026-02-03 |
| Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Rituximab, Prednisone - Idiopathic Nephrotic Syndrome, Minimal Change Disease | Phase 3 | Unknown | Radboud University Medical Center | 40 | 2018-08-22 | 2018-08-27 |
| Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) sparsentan, Irbesartan - Focal Segmental Glomerulosclerosis | Phase 3 | Completed | Travere Therapeutics, Inc. | 371 | 2018-04-17 | 2026-04-17 |
| Valproic Acid for Idiopathic Nephrotic Syndrome Valproic Acid - Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 / Phase 3 | Unknown | Universitair Ziekenhuis Brussel | 15 | 2016-10-01 | 2017-06-20 |
| Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood Rituximab, Placebo - Childhood Idiopathic Nephrotic Syndrome | Phase 2 / Phase 3 | Completed | University Hospital, Limoges | 26 | 2010-12-01 | 2015-03-23 |
| Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) Cyclosporin, Mycophenolate mofetil and Dexamethasone - Glomerulosclerosis, Focal | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 192 | 2004-11-01 | 2026-09-18 |
| Steroid Treatment for Kidney Disease Oral dexamethasone - Nephrosis, Focal Lipoid Glomerulosclerosis | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 8 | 2003-07-01 | 2011-10-28 |
| Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental prednisolone and mycophenolate mofetil, prednisolone and chlorambucil - Glomerulonephritis, Membranous, Glomerulosclerosis, Focal | Phase 3 | Completed | Hospital Authority, Hong Kong | 16 | 2003-01-01 | 2013-10-23 |
Nephrosis, Lipoid (6) · Kidney Diseases (2) · Nephrotic Syndrome (2) · Glomerulonephritis, Membranous (1) · Macular dystrophy, corneal type 1 (1) · Nephrosis (1) · Osteoporosis (1) · Proteinuria (1)
Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Glomerulonephritis (11) · Male Urogenital Diseases (11) · Nephritis (11) · Urogenital Diseases (11) · Urologic Diseases (11) · Kidney Diseases (9) · Nephrosis (5) · Autoimmune Diseases (1) · Bone Diseases (1) · Bone Diseases, Metabolic (1) · Immune System Diseases (1) · Metabolic Diseases (1) · Musculoskeletal Diseases (1)
Prednisolone (3) · Dexamethasone (2) · Mycophenolic Acid (2) · Prednisone (2) · Rituximab (2) · Chlorambucil (1) · Cyclosporine (1) · Irbesartan (1) · Valproic Acid (1) · propagermanium (1) · sparsentan (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Bio-Thera Solutions (1) · Boehringer Ingelheim (1) · Dimerix Bioscience Pty Ltd (1) · Hospital Authority, Hong Kong (1) · Radboud University Medical Center (1) · The Hospital for Sick Children (1) · Travere Therapeutics, Inc. (1) · Universitair Ziekenhuis Brussel (1) · University Hospital, Limoges (1)
United States (5) · Belgium (4) · China (4) · France (4) · Argentina (3) · Australia (3) · Brazil (3) · Canada (3) · Denmark (3) · Germany (3) · Hong Kong (3) · Italy (3) · New Zealand (3) · Portugal (3) · Spain (3)
Aaron Friedman, MD (1) · Daniel TM Chan, Prof (1) · David Fuller (1) · Jack F Wetzels, MD, PhD (1) · Jeroen K Deegens, MD,PhD (1) · Marva Moxey-Mims, MD, FAAP (1) · Peter Janssens, MD (1) · Radko Komers, MD, PhD (1) · Rulan Parekh, MD MS (1)
PMID 35224732, PMID 40337980, PMID 21178977, PMID 21734640, PMID 33412162, PMID 34778952, PMID 35230699, PMID 37254256, PMID 37921461, PMID 38724717, PMID 39513526, PMID 40938675, PMID 41433094
2023 (1), 2025 (1), U01DK063385 (1), U01DK063455 (1), U01DK063490 (1), U01DK063549 (1)